Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Erytech Pharma receives orphan drug designation from FDA for ERY-ASP in acute myeloid leukemia


Wednesday, 2 Apr 2014 01:30am EDT 

Erytech Pharma SA:Announces that its lead product GRASPA/ERY-ASP 1 has been granted Orphan Drug Designation by United States Food and Drug Administration (FDA) for treatment of Acute Myeloid Leukemia (AML).This designation conveys special incentives to sponsor, including seven years of United States market exclusivity for the drug or biologic upon FDA approval, prescription drug user fee waiver and tax credits.